Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-D: Roll Over Study for Durvalumab
NCT05303532Phase 3Enrolling by invitation
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 31
01
Overview
A Phase 3 trial of durvalumab in cancer, sponsored by AstraZeneca. Started Apr 2022; status: enrolling by invitation.
02
Drugs
durvalumab
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05303532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303532.